1) The biggest worry for vaccines about the new UK variant is the N501Y mutation in the receptor binding domain. This is also a mutation that appears when SARS-CoV-2 is mouse adapted. A paper looking at that found....

2)...that an experimental RBD-based vaccine still worked. I am not 100% sure the vaccine was based on N501, but I assume so. That would already be some good news. In general, I am not to worried about the impact of the new variant on vaccines. https://science.sciencemag.org/content/369/6511/1603

3) The other thing to keep in mind is, that both the Pfizer and Moderna vaccines protected after one shot, when neutralizing antibodies were super low in the vaccinees, meaning that likely a low titer is sufficient for protection. Titers are very high after the second shot.....

4).....so even IF the new variant would have an impact and lower the neutralizing potential a few fold, there is likely still enough antibody there to provide protection. My 2 cents.

5) And @profvrr just alerted me about this excellent @PaulBieniasz paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723407/ - at least the three human anti-RBD mAbs described here are not affected by N501Y